Skip to main navigation

menu

Aclaris - Corp Menu

About Us »
« Back
Research »
« Back
Partnerships
Careers
Citizenship »
« Back
Investors »
« Back

Aclaris - Extras Menu

Media resources
Contact us

Aclaris - Corp Menu

About Us »
« Back
Research »
« Back
Partnerships
Careers
Citizenship »
« Back
Investors »
« Back

Aclaris - Investor Relations

Investor Overview
Stock Information
Press Releases
Events
SEC Filings
Corporate Governance
Investor Presentations
Investor FAQs
Email Alerts

Investor Contact

For investor related questions, please email

investors@aclaristx.com

Investor Overview

Stock quote

VOLUME:

View stock performance »

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor Overview

Press Releases

December 5, 2023

Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia

November 13, 2023

Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update

November 6, 2023

Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

Events

Nov 13, 2023
8:00 AM EST

Aclaris Therapeutics Call to Discuss Zunsemetinib Phase 2b Rheumatoid Arthritis Trial Results

Sep 26, 2023
10:30 AM EDT

Aclaris Therapeutics at 2023 Cantor Global Healthcare Conference

Jun 14, 2023
4:40 PM PDT

Aclaris Therapeutics at 44th Annual Goldman Sachs Healthcare Conference

Feature Presentation

Aclaris Therapeutics Presents ATI-450 Phase 2b Rheumatoid Arthritis Data

Aclaris - Footer Menu

Terms of Use
Privacy Policy
Contact Us
Fraudulent Activity Notice

© 2023 Aclaris Therapeutics, Inc. All rights reserved. Unless otherwise noted, all trademarks referenced on this page are owned by Aclaris Therapeutics.